Publications by authors named "Mark L Levitt"

Article Synopsis
  • Patients with severe COVID-19 pneumonia have limited treatment options, and opaganib is an oral medication being researched to help those hospitalized.
  • A clinical trial conducted in 57 locations from August 2020 to July 2021 compared opaganib to a placebo over 14 days, focusing on whether patients could stop needing supplemental oxygen by day 14.
  • Although the primary results showed no significant general benefit, post-hoc analysis indicated that patients with low oxygen levels at baseline may experience better outcomes with opaganib, including reduced intubation rates and lower mortality, suggesting the need for further studies in this specific group.
View Article and Find Full Text PDF
Article Synopsis
  • Upamostat is a potent oral serine protease inhibitor that targets trypsin enzymes and uPA, which are linked to cancer invasion, while opaganib selectively inhibits sphingosine kinase 2 involved in cancer growth.
  • The study aimed to evaluate the antitumor effects of upamostat and opaganib, both separately and together, on cholangiocarcinoma tumors in nude mice.
  • Results indicated that treatments with upamostat, opaganib, or their combination significantly reduced tumor volumes compared to the control group.
View Article and Find Full Text PDF

The Covid-19 pandemic driven by the SARS-CoV-2 virus continues to exert extensive humanitarian and economic stress across the world. Although antivirals active against mild disease have been identified recently, new drugs to treat moderate and severe Covid-19 patients are needed. Sphingolipids regulate key pathologic processes, including viral proliferation and pathologic host inflammation.

View Article and Find Full Text PDF
Article Synopsis
  • Opaganib, an oral medication that inhibits sphingosine kinase-2 and has antiviral and anti-inflammatory effects, was tested for its potential benefits in treating moderate to severe COVID-19 pneumonia, particularly focusing on safety and its impact on oxygen needs and hospital stay duration.
  • The study was a Phase 2a, randomized, double-blind, placebo-controlled trial involving 42 patients in the US, where 23 received opaganib and 19 received a placebo for up to 14 days.
  • Results showed no major safety issues, with lower adverse events in the opaganib group, and initial evidence suggested opaganib may help reduce oxygen requirements and potentially allow for quicker hospital discharge, warranting further research.
View Article and Find Full Text PDF

Introduction: To determine the 1-year survival, response rate, and toxicity for patients with limited stage small cell lung cancer treated with the combination of cisplatin plus etoposide plus paclitaxel with delayed concurrent (starting with cycle 3) high dose thoracic radiotherapy.

Patients And Methods: Patients with previously untreated limited stage small cell lung cancer, Easter Cooperative Oncology Group performance status of 0-2 and adequate organ function were eligible. Cycles 1 and 2 of chemotherapy consisted of paclitaxel 170 mg/m intravenous day 1, etoposide 80 mg/m intravenous days 1 to 3, and cisplatin 60 mg/m intravenous day 1 followed by filgrastim 5 microg/kg subcutaneously days 4 to 13.

View Article and Find Full Text PDF

Aims And Background: To analyze the efficacy and toxicity of adjuvant chemotherapy followed by whole abdominal irradiation in the treatment of resectable gastric cancer with positive lymph nodes.

Methods And Study Design: Between 1996 and 1999, 10 patients with node-positive gastric cancer underwent complete gross resection and were treated by postoperative chemoradiotherapy. The chemotherapy regimen consisted of 5-fluorouracil, 1000 mg/m2/day as a 96-hr continuous infusion on day 1, and cisplatin, 100 mg/m2 on day 2, every 21 days.

View Article and Find Full Text PDF

Objective: To determine whether the use of adjuvant radiation in the treatment of invasive thymic tumors affects survival and to identify prognostic factors.

Methods: The files of 47 patients with thymic tumors treated by adjuvant radiation in our institute from 1984 to 2003 were reviewed for data on prognosis and survival. All patients underwent thoracotomy followed by either total macroscopic resection (n = 42) or biopsy (n = 5).

View Article and Find Full Text PDF

Forty-four specimens of non-malignant and malignant human lung tissue, taken from patients with non-small cell lung cancer (NSCLC), were examined for the expression of wild-type p53, mutant p53, and bcl-2 and the occurrence of programmed cell death (apoptosis). Wild-type p53 expression peaked in peritumoral and metaplastic samples, whereas mutant p53, bcl-2 and apoptosis were first detected in metaplasia and increased with progression to carcinoma. Bcl-2 positive samples had lower levels of apoptosis than bcl-2 negative samples and was independent of wild-type or mutant p53 expression.

View Article and Find Full Text PDF

Ceramide has been proposed as a second messenger for stress-induced apoptosis. By characterization of murine melanoma cells and their E1A transfectants, we found several lines of evidences against the role of ceramide as a second messenger for ultraviolet (UV)-induced apoptosis. First, although E1A transfected melanoma cells were more sensitive to UV-induced apoptosis than parental cells, the relative endogenous ceramide elevation induced by UV was greater in parental cells than in E1A transfectants.

View Article and Find Full Text PDF